The city of Pittsburgh, Pennsylvania, currently has 38 active clinical trials seeking participants for Lymphoma research studies.
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Recruiting
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Solid Tumor, Adult Lymphoma
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Allegheny Health Network (AHN) West Penn Hospital, Pittsburgh, Pennsylvania
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma